全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
药学学报  2014 

外排型转运体与cyp450酶所介导的药物相互作用

, PP. 590-595

Keywords: p-糖蛋白,多药耐药相关蛋白,乳腺癌耐药蛋白,细胞色素p450,药物相互作用

Full-Text   Cite this paper   Add to My Lib

Abstract:

多种药物同时给药后药物间相互作用能引发许多不良反应和治疗上的困难。引起这种药物相互作用的主要因素包括药物外排型转运体:p-糖蛋白(p-glycoprotein,p-gp,mdr1)、多药耐药相关蛋白(multidrugresistanceassociatedprotein,mrp)以及乳腺癌耐药蛋白(breastcancerresistanceprotein,bcrp)3种abc转运体以及药物代谢酶细胞色素p450(cyp450)。近年来,大量研究发现决定口服药物生物利用度的主要因素是肠道细胞中cyp3a对已吸收药物的生物转化作用和肠道细胞中p-gp对已吸收药物的主动外排作用。同为cyp3a和(或)p-gp底物的药物,当其与cyp3a和(或)p-gp的抑制剂同时服用后,药物的口服生物利用度可能升高。mrp、bcrp与p-gp同属药物的外排泵,与p-gp有重叠的底物特异性。mrp及bcrp与代谢酶cyp3a之间也存在着相似于p-gp的药物相互作用。本文从外排型转运体的类型、参与药物代谢的主要cyp450酶家族cyp3a、临床上由外排型转运体及代谢酶共同介导的药物相互作用和体外研究方法等方面进行综述。

References

[1]  bruyèrea,declèvesx,bouzomf,etal.effectofvariationsintheamountsofp-glycoprotein(abcb1),bcrp(abcg2)andcyp3a4alongthehumansmallintestineonpbpkmodelsforpredictingintestinalfirstpass[j].molpharm,2010,7:1596-1607.
[2]  huoxk,liuq,wangcy,etal.enhancementeffectofp-gpinhibitorsontheintestinalabsorptionandantiproliferativeactivityofbestatin[j].eurjpharmsci,2013,50:420-428.
[3]  liuzh,liukx.thetransportersofintestinaltractandtheirstudymethods[j].actapharmsin(药学学报),2011,46:370-376.
[4]  mohnc,häckerhg,hilgerra,etal.definingtheroleofmrp-mediatedeffluxandglutathioneindetoxificationofoxaliplatin[j].pharmazie,2013,68:622-627.
[5]  conseilg,colesp.twopolymorphicvariantsofabcc1selectivelyalterdrugresistanceandinhibitorsensitivityofthemultidrugandorganicaniontransportermrp1[j].drugmetabdispos,2013,41:2187-2196.
[6]  arendc,brandmannm,dringenr.theantiretroviralproteaseinhibitorritonaviracceleratesglutathioneexportfromculturedprimaryastrocytes[j].neurochemres,2013,38:732-741.
[7]  zhawb,wanggj,xuwr,etal.inhibitionofp-glycoproteinbyhivproteaseinhibitorsincreasesintracellularaccumulationofberberineinmurineandhumanmacrophages[j].plosone,2013,8:e54349.
[8]  hulotjs,villarde,maguya,etal.amutationinthedrugtransportergeneabcc2associatedwithimpairedmethotrexateelimination[j].pharmacogenetgenomics,2005,15:277-285.
[9]  weissj,rosej,storchch,etal.modulationofhumanbcrp(abcg2)activitybyanti-hivdrugs[j].jantimicrobchemother,2007,59:238-245.
[10]  weissj,theiled,ketabi-kiyanvashn,etal.inhibitionofmrp1/abcc1,mrp2/abcc2,andmrp3/abcc3bynucleoside,nucleotide,andnon-nucleosidereversetranscriptaseinhibitors[j].drugmetabdispos,2007,35:340-344.
[11]  nebertdw,wikvallk,millerwl.humancytochromesp450inhealthanddisease[j].philostransrsoclondbbiolsci,2013,368:20120431.
[12]  morónb,vermaak,dasp,etal.cyp3a4-catalyzedsimvastatinmetabolismasanon-invasivemarkerofsmallintestinalhealthinceliacdisease[j].amjgastroenterol,2013,108:1344-1351.
[13]  zhangyh,lum,sunxr,etal.expressionandactivityofp-glycoproteinelevatedbydexamethasoneinculturedretinalpigmentepitheliuminvolveglucocorticoidreceptorandpregnanexreceptor[j].investophthalmolvissci,2012,53:3508-3515.
[14]  xiew,barwickjl,simoncm,etal.reciprocalactivationofxenobioticresponsegenesbynuclearreceptorssxr/pxrandcar[j].genesdev,2000,14:3014-3023.
[15]  tzamelii,pissiosp,schuetzeg,etal.thexenobioticcompound1,4-bis[2-(3,5-dichloropyridyloxy)]benzeneisanagonistligandforthenuclearreceptorcar[j].molcellbiol,2000,20:2951-2958.
[16]  pald,mitraak.mdr-andcyp3a4-mediateddrug-herbalinteractions[j].lifesci,2006,78:2131-2145.
[17]  pald,mitraak.mdr-andcyp3a4-mediateddrug-druginteractions[j].jneuroimmunepharmacol,2006,1:323-339.
[18]  patelj,buddhab,deys,etal.invitrointeractionofthehivproteaseinhibitorritonavirwithherbalconstituents:changesinp-gpandcyp3a4activity[j].amjther,2004,11:262-277.
[19]  ieirii,tsunemitsus,maedak,etal.mechanismsofpharmacokineticenhancementbetweenritonavirandsaquinavir;micro/smalldosingtestsusingmidazolam(cyp3a4),fexofenadine(p-glycoprotein),andpravastatin(oatp1b1)asprobedrugs[j].jclinpharmacol,2013,53:654-661.
[20]  pald,mitraak.cyp3a4andmdrmediatedinteractionsindrugtherapy[j].clinresregulaff,2006a,23:125-163.
[21]  kharasched,bedynekps,walkera,etal.mechanismofritonavirchangesinmethadonepharmacokineticsandpharmacodynamics:ii.ritonavireffectsoncyp3aandp-glycoproteinactivities[j].clinpharmacolther,2008,84:506-512.
[22]  kharasched,stubbertk.cytochromep4503adoesnotmediatetheinteractionbetweenmethadoneandritonavir/lopinavir[j].drugmetabdispos,2013,41:2166-2174.
[23]  taylorle,swant,matthewsgv.managementofhepatitiscvirus/hivcoinfectionamongpeoplewhousedrugsintheeraofdirect-actingantiviral-basedtherapy[j].clininfectdis,2013,57:s118-s124.
[24]  tourniern,chevillardl,megarbaneb,etal.interactionofdrugsofabuseandmaintenancetreatmentswithhumanp-glycoprotein(abcb1)andbreastcancerresistanceprotein(abcg2)[j].intjneuropsychopharmacol,2010,13:905-915.
[25]  fosterb,twycrossr,mihalyom,etal.buprenorphine[j].jpainsymptommanage,2013,45:939-949.
[26]  burgerdm,agarwalas,childm,etal.effectofrifampinonsteady-statepharmacokineticsofatazanavirwithritonavirinhealthyvolunteers[j].antimicrobagentschemother,2006,50:3336-3342.
[27]  gallegol,barreirop,lópez-iborjj.psychopharmacologicaltreatmentsinhivpatientsunderantiretroviraltherapy[j].aidsrev,2012,14:101-111.
[28]  venkatakrishnank,greenblattdj,vonmoltkell,etal.alprazolamisanothersubstrateforhumancytochromep450-3aisoforms[j].jclinpsychopharmacol,1998,18:256.
[29]  vanwaterschootrab,schinkelah.acriticalanalysisoftheinterplaybetweencytochromep4503acyp3aandp-glycoprotein:insightsfromknockoutandtransgenicmice[j].pharmacolrev,2011,63:390-410.
[30]  pald,kwatrad,minocham,etal.effluxtransporters-andcytochromep-450-mediatedinteractionsbetweendrugsofabuseandantiretrovirals[j].lifesci,2011,88:959-971.
[31]  heikkinenat,friedleina,lamerzj,etal.massspectrometry-basedquantificationofcypenzymestoestablishinvitro/invivoscalingfactorsforintestinalandhepaticmetabolisminbeagledog[j].pharmres,2012,29:1832-1842.
[32]  haslamis,pitrea,schuetzjd,etal.protectionagainstchemotherapy-inducedalopecia:targetingatp-bindingcassettetransportersinthehairfollicle?[j].trendspharmacolsci,2013,34:599-604.
[33]  katragaddas,buddab,anandbs,etal.roleofeffluxpumpsandmetabolizingenzymesindrugdelivery[j].expertopindrugdeliv,2005,2:683-705.
[34]  rongzh,xuyj,zhangcl,etal.evaluationofintestinalabsorptionofamtolmetinguacylinrats:breastcancerresistantproteinasaprimarybarrieroforalbioavailability[j].lifesci,2013,92:245-251.
[35]  wein,sunh,liugt.advancesinthetargetingatpbindingcassettetransporterstoovercometumormulti-drugresistance[j].actapharmsin(药学学报),2010,45:1205-1211.
[36]  urquhartbl,tironarg,kimrb.nuclearreceptorsandtheregulationofdrug-metabolizingenzymesanddrugtransporters:implicationsforinterindividualvariabilityinresponsetodrugs[j].jclinpharmacol,2007,47:566-578.
[37]  schmittc,riekm,wintersk,etal.unexpectedhepatotoxicityofrifampinandsaquinavir/ritonavirinhealthymalevolunteers[j].archdruginf,2009,2:8-16.
[38]  wenningla,hanleywd,brainarddm,etal.effectofrifampin,apotentinducerofdrug-metabolizingenzymes,onthepharmacokineticsofraltegravir[j].antimicrobagentschemother,2009,53:2852-2856.
[39]  mudradr,desinoke,desaipv.insilico,invitroandinsitumodelstoassessinterplaybetweencyp3aandp-gp[j].currdrugmetab,2011,12:750-773.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133